Literature DB >> 18575270

Cell stress proteins: novel immunotherapeutics.

Stuart K Calderwood1, Jianlin Gong, Jimmy R Theriault, Salamatu S Mambula, Philip J Gray.   

Abstract

Heat shock proteins (HSPs) play important roles in the immune system as carriers of tumour antigens and inflammatory agents. The HSPs are abundantly expressed stress proteins intrinsic to all cellular life, permitting proteins to carry out essential enzymic, signalling and structural functions within the tightly crowded milieu of the cell. To carry out these tasks, HSPs are equipped with a domain that binds unstructured sequences in polypeptides and a N-terminal ATPase domain that controls the opening and closing of the peptide-binding domain. HSPs can, using these domains, capture antigens processed by partial proteolysis in the cytoplasm of cancer cells. HSP/peptide complexes formed in the cytoplasm can then be secreted to take part in immune surveillance. Extracellular Hsp70 interacts with receptors on antigen presenting cells (APCs) either during episodes of cell death and lysis in vivo or during vaccination. A number of candidate receptors for Hsp70 on APCs have been proposed to take part in the antitumour immune function including the alpha2 macroglobulin receptor CD91, Toll-like receptors, the signalling receptor CD40 and a number of scavenger receptors. Finally, Hsp70 complexes are able to deliver antigens to MHC class I and II molecules on the APC cell surface and lead to the presentation of tumour antigens to T lymphocytes. HSP-antigen complexes have proven effective in the treatment of rodent tumours in preclinical studies and are now undergoing clinical trials for treatment of human cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575270     DOI: 10.1002/9780470754030.ch9

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  6 in total

Review 1.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

2.  Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.

Authors:  Desheng Weng; Baizheng Song; Shigeo Koido; Stuart K Calderwood; Jianlin Gong
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

3.  T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1.

Authors:  Jianlin Gong; Bangmin Zhu; Ayesha Murshid; Hideki Adachi; Baizheng Song; Allegra Lee; Chunlei Liu; Stuart K Calderwood
Journal:  J Immunol       Date:  2009-07-29       Impact factor: 5.422

4.  Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101.

Authors:  Marc J Braunstein; Sadeaqua S Scott; Craig M Scott; Shannon Behrman; Peter Walter; Peter Wipf; Jeremy D Coplan; William Chrico; Danielle Joseph; Jeffrey L Brodsky; Olcay Batuman
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

5.  Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.

Authors:  Sabine Tischer; Megan Basila; Britta Maecker-Kolhoff; Stephan Immenschuh; Mathias Oelke; Rainer Blasczyk; Britta Eiz-Vesper
Journal:  J Transl Med       Date:  2011-10-12       Impact factor: 5.531

6.  Heat shock proteins: conditional mediators of inflammation in tumor immunity.

Authors:  Stuart K Calderwood; Ayesha Murshid; Jianlin Gong
Journal:  Front Immunol       Date:  2012-04-09       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.